| Market Capitalization (Millions $) |
2,300 |
| Shares
Outstanding (Millions) |
151 |
| Employees |
239 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-587 |
| Cash Flow (TTM) (Millions $) |
108 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Biohaven Ltd is a clinical-stage biopharmaceutical company that is focused on developing and commercializing drugs for the treatment of neurological and neuropsychiatric disorders. The company was founded in 2013 and is headquartered in New Haven, Connecticut.
Biohaven's mission is to deliver breakthrough, innovative therapies to patients suffering from neurological and neuropsychiatric disorders who have unmet medical needs. The company's key areas of research and development (R&D) include migraine and other headaches, spinocerebellar ataxia, Alzheimer's disease, and anxiety disorders.
Migraine and Headache Disorders:
Biohaven has developed several products that are designed to target different aspects of migraine and headache disorders. The company's lead drug candidate, Rimegepant, is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has demonstrated efficacy in clinical studies for the acute treatment of migraine. Biohaven is also developing other CGRP receptor antagonists, including BHV-3500 and BHV-0223, and a glutamate modulator, Troriluzole, for the prevention of migraine and related disorders.
Spinocerebellar Ataxia:
Spinocerebellar ataxia (SCA) is a group of genetic disorders that affect the coordination and movement of the body. Biohaven is developing a drug candidate, Troriluzole, which is designed to target the underlying pathology of SCA by modulating the levels of glutamate in the brain. Troriluzole has demonstrated potential benefits in preclinical models of multiple SCAs, and Biohaven is currently conducting clinical trials to evaluate its safety and efficacy in patients with SCA.
Alzheimer's Disease:
Alzheimer's disease is a neurodegenerative disorder that affects memory, cognitive function, and behavior. Biohaven is developing a drug candidate, Verdiperstat, which is a small molecule inhibitor of myeloperoxidase (MPO), an enzyme that is involved in the inflammation associated with Alzheimer's disease and other neuroinflammatory conditions. Biohaven is currently evaluating Verdiperstat in a Phase 2/3 clinical trial for the treatment of Alzheimer's disease.
Anxiety Disorders:
Biohaven is also developing a drug candidate, Troriluzole, for the treatment of anxiety disorders. Troriluzole is a glutamate modulator that has demonstrated potential benefits in preclinical models of anxiety and depression. Biohaven is currently conducting clinical trials to evaluate its safety and efficacy in patients with generalized anxiety disorder.
Biohaven's R&D efforts are supported by a strong intellectual property portfolio, which includes patents covering its drug candidates and their methods of use. The company has a team of experienced scientists, researchers, and clinicians who are dedicated to advancing its pipeline of therapies and bringing them to market as quickly and efficiently as possible.
Overall, Biohaven is a dynamic biopharmaceutical company that is focused on developing innovative therapies to address significant unmet medical needs in neurological and neuropsychiatric disorders. With its talented team, strong pipeline of drug candidates, and commitment to improving the lives of patients, Biohaven is well-positioned to be a leader in its field.
Company Address: c/o Biohaven Pharmaceuticals, Inc. New Haven 6510 CT
Company Phone Number: 404-0410 Stock Exchange / Ticker: NYSE BHVN
|
1.75%